Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients

Abramov,Yoram; Carmi,Shani; Anteby,Shaoul  O.; Ringel,Israel

doi:10.3892/or.2012.2071

Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients

Authors:
- Yoram Abramov
- Shani Carmi
- Shaoul O. Anteby
- Israel Ringel
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Carmel Medical Center, Technion University, Rappaport Faculty of Medicine, Haifa, Israel, Department of Pharmacology, Hadassah Hebrew University Medical School, Jerusalem, Israel, Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical School, Jerusalem, Israel
Published online on: October 5, 2012 https://doi.org/10.3892/or.2012.2071
Pages: 321-328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We aimed to determine whether cells obtained from malignant ovarian tumors had different ex vivo 1H- and 31P (phosphorus-31)-magnetic resonance (MR) spectra compared to cells obtained from benign ovarian cysts. In addition, we aimed to assess the metabolic effects of chemotherapy on malignant cells obtained from peritoneal effusions of ovarian cancer patients. We included 20 ovarian cancer patients undergoing explorative laparotomy for tumor resection, 15 patients undergoing oophorectomy for benign ovarian cysts and 8 patients with advanced ovarian cancer with cancerous peritoneal effusion undergoing palliative percutaneous drainage. Ovarian and metastatic tissues were obtained from all patients undergoing laparotomy and analyzed using 1H magnetic resonance spectroscopy (MRS). Cancerous cells from peritoneal effusions were incubated with 3 different anti-mitotic drugs (paclitaxel, cisplatin and carboplatin) at LC50 and the consequent metabolic changes were monitored using 31P-MRS. 1H-MRS revealed significantly higher intracellular lactate levels in cells obtained from ovarian tumors, most prominently in the moderately to poorly differentiated histological types, while total choline (Chol) compounds were higher in the moderately to poorly differentiated subgroup only. Ovarian cancer cells obtained from peritoneal effusions showed a significantly decreased glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE) and uridine diphospho-sugar (UDPS) levels following ex vivo exposure to all 3 anti-mitotic drugs. Ex vivo 1H-MRS identified significant metabolic differences between cells obtained from ovarian tumors compared to those originating in benign ovarian cysts, including increased lactate and total choline compound levels. The 31P-MRS technique allowed characterization and monitoring of metabolic changes occurring in ovarian cancer cells in response to chemotherapy.

View Figures

View References

1	National Cancer Institute. http://www.cancer.gov.
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
3	Tennant DA, Durán RV, Boulahbel H and Gottlieb E: Metabolic transformation in cancer. Carcinogenesis. 30:1269–1280. 2009. View Article : Google Scholar : PubMed/NCBI
4	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
5	Wise DR, DeBerardinis RJ, Mancuso A, et al: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 105:18782–18787. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zupke C and Foy B: Nuclear magnetic resonance analysis of cell metabolism. Curr Opin Biotechnol. 6:192–197. 1995. View Article : Google Scholar : PubMed/NCBI
7	Bel JD and Bhakoo KK: Metabolic changes underlying ³¹P MR spectral alterations in human hepatic tumours. NMR Biomed. 11:354–359. 1998.
8	Sterin M, Cohen JS, Mardor Y, Berman E and Ringel I: Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a ³¹P-magnetic resonance spectroscopy study. Cancer Res. 61:7536–7543. 2001.PubMed/NCBI
9	Massuger LF, van Vierzen PBJ, Engelke U, Heerschap A and Wevers RA: ¹H-magnetic resonance spectroscopy: a new technique to discriminate benign from malignant ovarian tumors. Cancer. 82:1726–1730. 1998. View Article : Google Scholar : PubMed/NCBI
10	Boss EA, Moolenaar SH, Massuger LFAG, Boonstra H, Engelke UFH, de Jong JGN and Wevers RA: High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed. 13:297–305. 2000. View Article : Google Scholar : PubMed/NCBI
11	Podo F: Tumour phospholipid metabolism. NMR Biomed. 12:413–439. 1999. View Article : Google Scholar : PubMed/NCBI
12	Tosi R and Tugnoli V: Nuclear Magnetic Resonance Spectroscopy in the Study of Neoplastic Tissue. Nova Science Publishers Inc.; New York, NY: pp. 1–444. 2005
13	Gillies RJ and Morse DL: In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 7:287–326. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kwock L, Smith JK, Castillo M, et al: Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol. 7:859–868. 2006. View Article : Google Scholar : PubMed/NCBI
15	Mackinnon WB, Russell P, May GL and Mountford CE: Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy. Int J Gynecol Cancer. 5:211–221. 1995. View Article : Google Scholar : PubMed/NCBI
16	Wallace JC, Raaphorst GP, Somorjai RL, et al: Classification of ¹H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med. 38:569–576. 1997.
17	Slupsky CM, Steed H, Wells TH, et al: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 16:5835–5841. 2010. View Article : Google Scholar : PubMed/NCBI
18	Podo F, Canevari S, Canese R, Pisanu ME, Ricci A and Iorio E: MR evaluation of response to targeted treatment in cancer cells. NMR Biomed. 24:648–672. 2011.PubMed/NCBI
19	Katz-Brull R, Lavin PT and Lenkinski RE: Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 94:1197–1203. 2002. View Article : Google Scholar : PubMed/NCBI
20	Aboagye EO and Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 59:80–84. 1999.
21	Glunde K, Jie C and Bhujwalla M: Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 64:4270–4276. 2004. View Article : Google Scholar : PubMed/NCBI
22	Glunde K, Ackerstaff E, Natarajan K, Artemov D and Bhujwalla ZM: Real-time changes in ¹H and ³¹P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med. 48:819–825. 2002.
23	Ackerstaff E, Pflug BR, Nelson JB and Bhujwalla ZM: Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 61:3599–3603. 2001.
24	Iorio E, Mezzanzanica D, Alberti P, et al: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65:9369–9376. 2005. View Article : Google Scholar : PubMed/NCBI
25	Canese R, PIsanu ME, Mezzanzanica D, et al: Characterisation of in vivo ovarian cancer models by quantitative ¹H magnetic resonance spectroscopy and diffusion-weighted imaging. NMR Biomed. 25:632–642. 2012.PubMed/NCBI
26	Esseridou A, Di Leo G, Sconfienza LM, et al: In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy. Invest Radiol. 46:377–382. 2011. View Article : Google Scholar : PubMed/NCBI
27	Iorio E, Ricci A, Bagnoli M, Pisanu ME, et al: Activation of phosphtidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 70:2126–2135. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cheng LL, Chang IW, Smith BL and Gonzalez RG: Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson. 135:194–202. 1998. View Article : Google Scholar
29	Tessem MB, Swanson MG, Keshari KR, et al: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using ¹H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 60:510–516. 2008. View Article : Google Scholar : PubMed/NCBI
30	Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 51:349–353. 2001. View Article : Google Scholar : PubMed/NCBI
31	Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK and Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60:916–921. 2000.
32	Huang Z, Tong Y, Wang J and Huang Y: NMR studies of the relationship between the changes of membrane lipids and the cisplatin resistance of A549/DDP cells. Cancer Cell Int. 3:52003. View Article : Google Scholar : PubMed/NCBI
33	Hanauske AR, Depenbrock H, Shirvani D and Rastetter J: Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Eur J Cancer. 30A:1688–1694. 1994. View Article : Google Scholar
34	Chahine JMEH, Cribier S and Devaux PF: Phospholipid transmembrane domains and lateral diffusion in fibroblasts. Proc Natl Acad Sci USA. 90:447–451. 1993. View Article : Google Scholar : PubMed/NCBI
35	Pike MC, Kredich NM and Snyderman R: Influence of cytoskeletal assembly on phosphatidylcholine synthesis in intact phagocytic cells. Cell. 20:373–379. 1980. View Article : Google Scholar : PubMed/NCBI
36	Fallbrook A, Turenne SD, Mamalias N, Kish SJ and Ross BM: Phosphatidylcholine and phosphatidylethanolamine metabolites may regulate brain phospholipid catabolism via inhibition of lysophospholipase activity. Brain Res. 834:207–210. 1999. View Article : Google Scholar